首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

北美T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

市場調查報告書

商品編碼

1452634

北美T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

North America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 70 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年北美T細胞治療市值為16.4552億美元，預計2030年將達到53.2975億美元；預計2022年至2030年CAGR為15.8%。

T 細胞治療批准數量的增加推動了北美 T 細胞治療市場的發展

細胞療法的優點包括標靶治療、更快、更有效的恢復以及減少副作用。由於 FDA 批准的產品的可用性，細胞療法在全球範圍內被廣泛採用。以下是近年來FDA批准的T細胞治療產品清單：

例如，2022年6月，百時美施貴寶的Breyanzi (lisocabtagene maraleucel) 獲得FDA 批准，這是一種CD19 定向嵌合抗原受體(CAR) T 細胞療法，用於治療成人大B 細胞淋巴瘤(LBCL ) 患者。

2022年2月，美國食品藥物管理局(FDA) 批准Yescarta (axicabtagene ciloleucel) CAR T 細胞療法用於治療一線化學免疫療法難治或一線化學免疫療法12 個月內復發的大B 細胞淋巴瘤成人患者。 Yescarta 是第一個獲得全國綜合癌症網路 (NCCN) 1 類推薦的 CAR T 細胞療法。

2022年2月，FDA核准了ciltacabtagene autoleucel（商品名CARVYKTI）用於治療經過四線或四線以上治療（包括蛋白酶體抑制劑、免疫調節劑和抗CD38單株抗體）後復發或難治性多發性骨髓瘤的成年患者。

2022年1月，FDA核准Kimmtrak（tebentafusp-tebn）用於治療HLA-A*02:01陽性的不可切除或轉移性葡萄膜黑色素瘤患者。

2021年3月，Abecma（idecabtagene vicleucel）被FDA核准用於治療復發或難治性多發性骨髓瘤。該療法是一種針對 B 細胞成熟抗原 (BCMA) 的基因改造自體 T 細胞免疫療法，適用於治療患有難治性多發性骨髓瘤的成年患者。

因此，越來越多的 T 細胞療法獲批正在推動北美 T 細胞療法市場的成長。

北美T細胞治療市場概況

北美的 T 細胞治療市場分為美國、加拿大和墨西哥。到2022 年，美國在該地區佔據最大的市場佔有率，並且由於癌症和自體免疫疾病等慢性疾病負擔的增加、研發活動的成長以及強大而成熟的市場佔有率，預計將在預測期內繼續佔據主導地位。市場參與者。此外，隨著 CAR T 細胞療法臨床研究的增加，北美市場預計在預測期內將會成長。據CDC稱，2020年美國報告了1,603,844例新癌症病例，602,347人死亡。預計2023年美國將有184,720人被診斷出患有白血病、淋巴瘤或骨髓瘤。

Tisagenlecleucel（KymriahTM，Novartis，Morris Plains，新澤西州，美國）和axicabtagene ciloleucel（YescartaTM，Gilead Sciences Canada，El Segundo，CA，US）是加拿大衛生部於2018 年在加拿大批准的首批兩種商業化CAR TCAR T細胞。分別為2019年。兩者都是第二代抗 CD19 CAR T 細胞，被批准用於患有 r/r DLBCL、原發性縱隔 B 細胞淋巴瘤和轉化濾泡性淋巴瘤的成年患者。此外，加拿大主導的癌症免疫療法-01 (CLIC-01) 是加拿大第一個引入 CAR T 細胞療法的計畫。它使用不同類型的細胞製造技術，提供更便宜、更公平的治療。自2022 年3 月起，位於哈利法克斯的伊麗莎白女王二世健康科學中心成為加拿大大西洋地區第一個在本地提供CAR T 細胞治療的機構。在此之前，被推薦接受這種高度個人化癌症藥物的新斯科細亞省患者必須前往境外旅行。國家接受治療。該計劃的實現得益於政府每年 670 萬美元的投資。因此，不斷增加的癌症病例和政府的措施推動了北美 T 細胞治療市場的發展。

北美 T 細胞治療市場收入及 2030 年預測（百萬美元）

北美T細胞治療市場細分

北美 T 細胞治療市場分為模式、治療類型、適應症和國家。

根據模式，北美 T 細胞治療市場分為研究和商業化。 2022年，商業化細分市場將佔據更大的市場佔有率。

根據治療類型，北美T細胞治療市場分為CAR T細胞療法和T細胞受體（TCR）療法。 2022年，CAR T細胞療法領域將佔據更大的市場佔有率。

根據適應症，北美 T 細胞治療市場分為血液惡性腫瘤和實體腫瘤。 2022 年，血液惡性腫瘤細分市場佔據最大市場。

根據國家/地區，北美 T 細胞治療市場分為美國、加拿大和墨西哥。 2022年，美國在北美T細胞治療市場佔有率中佔據主導地位。

Bluebird Bio Inc、Bristol-Myers Squibb Co、Cartesian Therapeutics Inc、Gilead Sciences Inc、Innovent Biologics Inc、Janssen Global Services LLC 和 Novartis AG 是北美 T 細胞治療市場的一些領先公司。

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the North America T cell therapy market growth.

North America T Cell Therapy Market Overview

The T-cell therapy market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with an increase in clinical studies in CAR T-cell therapies, the market in North America is expected to grow during the forecast period. According to CDC, 1,603,844 new cancer cases were reported and 602,347 people died in the US in 2020. An estimated 184,720 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2023.

Tisagenlecleucel (KymriahTM, Novartis, Morris Plains, NJ, US) and axicabtagene ciloleucel (YescartaTM, Gilead Sciences Canada, El Segundo, CA, US) were the first two CAR T-cells commercially available and approved in Canada by Health Canada in 2018 and 2019, respectively. Both are second-generation anti-CD19 CAR T-cells, approved for adult patients with r/r DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Moreover, Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) is the first to introduce CAR T-cell therapy in Canada. It uses a different kind of cell manufacturing that unveils less expensive and more equitable treatment. The Queen Elizabeth II Health Sciences Centre in Halifax became the first facility in Atlantic Canada to offer CAR T-cell therapy locally as of March 2022. Prior to this, Nova Scotia patients who were recommended for this highly personalized cancer medicine had to travel outside the country to receive the treatment. The program was made possible with a government investment of US$ 6.7 million annually. Thus, the rising cancer cases and initiative by the government fuel the T-cell therapy market in North America.

North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

North America T Cell Therapy Market Segmentation

The North America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the North America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the North America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the North America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the North America T cell therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America T cell therapy market share in 2022.

Bluebird Bio Inc, Bristol-Myers Squibb Co, Cartesian Therapeutics Inc, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the North America T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 North America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - North America Market Analysis

5.1 North America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

8.1 Overview
8.2 North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 North America T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America T Cell Therapy Market - Country Analysis

9.1 Overview

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Legend Biotech Corp
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Janssen Global Services LLC
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Cartesian Therapeutics Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America T Cell Therapy Market Segmentation
Table 2. North America T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Recent Organic Growth Strategies in T Cell Therapy Market
Table 16. Recent Inorganic Growth Strategies in the T Cell Therapy Market
Table 17. Glossary of Terms, North America T Cell Therapy Market

List Of Figures

Figure 1. North America T Cell Therapy Market Segmentation, By Country
Figure 2. North America T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America T Cell Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 15. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. US: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Canada: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Mexico: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Growth Strategies in T Cell Therapy Market